Lilly(Eli) & Company

NYSE: LLY
$921.49
+$6.45 (+0.7%)
Closing Price on September 20, 2024

LLY Articles

A new Jefferies research report features top pharmaceutical picks for the fourth quarter. Any of these top picks make good sense for long-term growth and income portfolios.
One smart thing for growth stock buyers is to focus on total return and buy large cap quality stocks that will do well regardless of the near-term economic news.
Eli Lilly shares had a bit of a boost on Wednesday after it was announced that one of its subsidiaries would be acquiring Boehringer Ingelheim Vetmedica.
A recent Merrill Lynch research report features the firm's top ideas for the fourth quarter. These eight stocks look like outstanding picks for growth stock accounts.
Any of these three top pharmaceutical companies makes an outstanding addition to more conservative portfolios. They are also far less volatile and act better than biotechs if the market gets dicey.
If there is one trend that has worked in America, it is the trend of betting on the public taking care of their pets. Now Merrill Lynch has issued a report on the state of animal health, with two Buy...
In a recent research note, the analysts at Merrill Lynch make a big move by adding a top utility company to the firm's well-respected US 1 list of stocks to Buy.
Despite recent market headwinds and volatility, there are strong underlying fundamentals among the large cap pharmaceuticals that are continuing to drive them forward.
Investors never take kindly to a 2.45% sell-off, like the one seen in the S&P 500, and they may be looking to shift into dividend-paying large caps, which will remain in demand as rates continue...
Credit Suisse has run bullish and bearish scenarios for what the firm feels is a reasonable upside and downside for each of its large cap pharmaceutical stocks.
A new Jefferies research report features the firm's top pharmaceutical stock picks in order of preference, and AbbVie stays in the top position.
As one of the largest pharmaceutical companies on the street, Eli Lilly helps to set the tempo for the industry. Currently the company is in the middle of a very dynamic product launch.
SunTrust Robinson Humphrey feels that the major pharmaceutical companies will outperform the rest of the year, and they cite new products, attractive dividends and solid performance as positives.
With yields plunging and the market getting very pricey, some top pharmaceutical stocks are starting to look like a great total return vehicle for the rest of this year and into 2017.
Viagra, the wildly successful erectile dysfunction pill, faces challenges from a generic version that will launch next year.